• Strategic Technologies

The Oxford Science Park sponsors the OXBA Innovation Award for the fourth year

Oxford, UK, 14 January 2019 - Oxfordshire companies which are progressing valuable innovations can apply now for The Oxford Science Park Innovation Award, one of 2019's Oxfordshire Business Awards (OXBA). The Oxford Science Park, one of the UK's leading parks for science and technology companies, is pleased to be sponsoring the award for the fourth year.

JP Morgan | Take home messages

Key M&As set a positive tone for JPM 2019, as the sector shrugged off US stock market setbacks at the end of 2018. First out of the blocks were GSK taking Tesaro in a £3.8bn deal (announced before the conference) and since ringing in the new year we’ve seen Takeda complete their acquisition of Shire, Bristol-Myers Squibb acquire Celgene in a record breaking £70bn deal and Eli Lilly purchase Loxo Oncology for £6.24bn. These large pharma deals show desire for a strategic pipeline and prove the inherent value of biotech as a driver of innovation. More than half of new drugs registered in the coming years are expected to be made by small companies which large players may then look to add to their portfolio. The outlook for M&As looks strong and venture are keen to put money to work knowing the

Video of the Week | NICE Evidence Standards Framework for Digital Health Technologies

As digital health innovations have developed at an increasing pace, it has been a challenge to identify which are clinically effective and offer economic value.

CEO Update | Monday 7 January 2019

Happy New Year everyone. I write this on my way to San Francisco to start the year at the JP Morgan conference. This look ahead to 2019 summarises my key themes for the year and closes with a quick summary of UK news that came out over the holiday period.   

Video of the week | The Future Of Immunology In the UK

What is the #FutureofImmunology in the UK? Watch to see Ailsa Bosworth MBE (Founder and CEO of the National Rheumatoid Arthritis Society), Peter Openshaw (President of the British Society for Immunology) and Lisa Olsen (Vice President, R&D, Head of Abbvie Bioresearch Centre) explain why the future is bright #AdvancingTogether 

Computer Aided Biology Pioneer Synthace Secures $25.6 Million in Series B Funding

Synthace Ltd today announced the closing of a $25.6m Series B financing round led by Horizons Ventures with additional investment from Luminous Ventures, SOSV and select other individual and large family office investors. Synthace will use the new funds to drive continued product development and build upon its cell and gene therapy customer base to accelerate global awareness of its solutions.

Genomics plc today announces second close of its Series B financing, raising a further £8 million, bringing the total round to £33 million

10 December 2018, OXFORD, UK -- Genomics plc, the data science company specialising in the use of human genetic information to improve drug development, today announced that it has successfully completed a second close of its Series B financing round. The second close, which was oversubscribed, raised an additional £8 million, bringing the total raised in the round to £33 million.

CEO Update | Monday 3 December

Today the government announced funding for a new Vaccines Manufacturing Innovation Centre to be built in Oxford. Led by the Jenner Institute, a partnership between the University of Oxford and the Pirbright Institute, the new centre has been awarded funding by UK Research and Innovation of £66 million through the UK government’s Industrial Strategy Challenge Fund (ISCF) Medicines Manufacturing challenge. Additional funding of £10 million will come from commercial and other partners, including Janssen Vaccines & Prevention B.V. and Merck Sharp and Dohme. The centre will be further supported by expertise and training from GE Healthcare. The core research teams will be drawn from academia and industry and will include significant new contributions from the London School of Hygiene & Tropical

Precision medicine heads to Namibia, courtesy of Global Gene Corp and UNAM

A nationwide genomics initiative in Namibia will bring the benefits of precision medicine to the southern African republic. Global Gene Corp is collaborating with the University of Namibia as well as the Namibian Ministry of Higher Education, Training and Innovation to make this health milestone a reality.

Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies

Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.